Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma (RADIOSARP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02787642
Recruitment Status : Recruiting
First Posted : June 1, 2016
Last Update Posted : September 18, 2018
Sponsor:
Collaborator:
National Cancer Institute, France
Information provided by (Responsible Party):
Institut Bergonié

Brief Summary:
A phase Ib study of Olaparib with concomitant radiotherapy in locally advanced/unresectable soft-tissue sarcoma.

Condition or disease Intervention/treatment Phase
Soft-tissue Sarcoma Drug: Olaparib Radiation: Concomitant Radiotherapy Phase 1

Detailed Description:
This is a multicenter, prospective phase Ib trial based on a dose escalation study design (3+3 traditional design) assessing four dose levels of Olaparib given with concomitant radiotherapy, followed by an expansion cohort.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 41 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma
Actual Study Start Date : January 2016
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Olaparib

Arm Intervention/treatment
Experimental: Olaparib in association with concomitant radiotherapy
Olaparib will be administered per os bi-daily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression. Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
Drug: Olaparib
Olaparib will be administered per os bidaily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression.

Radiation: Concomitant Radiotherapy
Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.




Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) of Olaparib evaluated up to six weeks after end of radiotherapy [ Time Frame: Until to six weeks after end of radiotherapy ]

Secondary Outcome Measures :
  1. Non-progression defined as CR, PR as per RECIST 1.1 [ Time Frame: 6-month ]
  2. Objective defined as CR or PR as per RECIST 1.1 [ Time Frame: 6-month ]
  3. Best objective response under treatment as per RECIST v 1.1 [ Time Frame: End of treatment,an average of 6 months ]
  4. Best response under treatment as per RECIST 1.1 [ Time Frame: End of treatment,an average of 6 months ]
  5. Progression-free survival (PFS) as per RECIST 1.1 [ Time Frame: 1 year ]
  6. Overall Survival (OS) [ Time Frame: 1 year ]
  7. Functional assessment graded using the Muskuloskeletal Tumour Society Rating Scale (Enneking, 1987) [ Time Frame: Day 1, Week 8 ]
  8. Pharmacokinetics PK measurements expressed as the AUC of Olaparib [ Time Frame: Weeks 1, 2, 5 ]
  9. Pharmacokinetics PK measurements expressed as half-life of Olaparib [ Time Frame: Weeks 1, 2, 5 ]
  10. Pharmacokinetics PK measurements expressed as the concentration peak of Olaparib [ Time Frame: Weeks 1, 2, 5 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histology: patients with soft-tissue sarcoma histologically confirmed by central review (Pr Coindre team), except if the diagnosis was already confirmed by the RRePS Network,
  2. Upper/Lower limb or trunk wall soft-tissue sarcoma,
  3. Age ≥ 18 years,
  4. Locally advanced or locally recurrent inoperable tumor, outside any previously irradiated field (inoperable status must be assessed by staff including a surgeon specialized in sarcoma),
  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2,
  6. Life expectancy ≥ 6 months,
  7. At least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements,
  8. Adequate hematological, renal, metabolic and hepatic function:

    • Haemoglobin ≥ 9 g/dL and no blood transfusions in the 14 days prior to study entry
    • Absolute neutrophil count (ANc) ≥ 1.5 x 109/L
    • Platelets ≥ 100 x 109/L
    • Total bilirubin ≤ 1.5 x upper limit of normality (ULN),
    • Alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) ≤ 2.5 x ULN,
    • Serum creatinine ≤ 150 μmol/L or creatinine clearance ≥ 50 mL/min (according to local institution) in case of serum creatinine > 150 μmol/L,
    • TP, INR ≤ 1.5 x ULN
  9. Women of childbearing potential must have a negative serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1. Female patients of child bearing potential and their partners, who are sexually active, must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for at least 1 month after last dose of study drug. Males patients, who are sexually active, must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for at least 3 month after last dose of study drug. Acceptable birth control methods are described in appendix 10.

    Subjects of non-childbearing potential are those who have:

    • Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments,
    • LH and FSH levels in the post menopausal range for women under 50,
    • radiation-induced oophorectomy with last menses >1 year ago,
    • chemotherapy-induced menopause with >1 year interval since last menses,
    • or surgical sterilisation (bilateral oophorectomy or hysterectomy).
  10. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up,
  11. Voluntary signed and dated written informed consent prior to any specific procedure,
  12. Patients with a French social security in compliance with the Law relating to biomedical research (Article L.1121-11 of French Public Health Code).

Exclusion Criteria:

  1. Any previous treatment with a PARP inhibitor, including Olaparib,
  2. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication,
  3. Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) and are receiving antiviral therapy,
  4. Patients with known active hepatic disease (i.e., Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids,
  5. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression (untreated and unstable for at least 28 days prior to study entry), superior vena cava syndrome, extensive bilateral lung disease on HRCT scan or any psychiatric disorder that prohibits obtaining informed consent,
  6. Patients with uncontrolled seizures,
  7. Men or women of childbearing potential who are not using an effective method of contraception as previously describes; women who are pregnant or breast feeding,
  8. No prior or concurrent malignant disease diagnosed or treated in the last 2 years, except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma,
  9. Patients receiving any systemic chemotherapy within 2 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used),
  10. Concomitant use of known CYP3A4 inhibitors such as ketokonazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir,
  11. Resting ECG with QTc > 470msec on 2 or more time points within a 24 hour period or family history of long QT syndrome,
  12. Blood transfusions within 14 days prior to study start,
  13. Patients with myelodysplastic syndrome/acute myeloid leukaemia,
  14. Major surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgery,
  15. Participation to a study involving a medical or therapeutic intervention in the last 30 days,
  16. Patient unable to follow and comply with the study procedures because of any geographical, familial, social or psychological reasons,
  17. Previous enrollment in the present study,
  18. Patients with a known hypersensitivity to olaparib or any of the excipients of the product.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02787642


Contacts
Layout table for location contacts
Contact: Paul SARGOS, MD p.sargos@bordeaux.unicancer.fr
Contact: Simone MATHOULIN-PELISSIER, MD-PhD s.mathoulin@bordeaux.unicancer.fr

Locations
Layout table for location information
France
Institut Bergonié Recruiting
Bordeaux, France, 33076
Contact: Paul SARGOS, MD       s.sargos@bordeaux.unicancer.fr   
Centre Oscar Lambret Not yet recruiting
Lille, France, 59020
Contact: Nicolas PENEL, MD-PhD       n-penel@o-lambret.fr   
Centre Léon Bérard Recruiting
Lyon, France, 69373
Contact: Marie-Pierre SUNYACH, MD       marie-pierre.sunyach@lyon.unicancer.fr   
Institut du Cancer de Montpellier Not yet recruiting
Montpellier, France, 34298
Contact: Carmen LLACER-MOSCARDO, MD       carmen.llacer@icm.unicancer.fr   
Institut Claudius Regaud - IUCT Recruiting
Toulouse, France, 31052
Contact: Christine CHEVREAU, MD       chevreau.christine@iuct-oncopole.fr   
Institut Gustave Roussy Not yet recruiting
Villejuif, France, 94800
Contact: Axel LE CESNE, MD       axel.lecesne@gustaveroussy.fr   
Sponsors and Collaborators
Institut Bergonié
National Cancer Institute, France

Layout table for additonal information
Responsible Party: Institut Bergonié
ClinicalTrials.gov Identifier: NCT02787642     History of Changes
Other Study ID Numbers: IB 2015-05
2015-003722-13 ( EudraCT Number )
First Posted: June 1, 2016    Key Record Dates
Last Update Posted: September 18, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Institut Bergonié:
Advanced soft-tissue sarcoma
Unresectable Soft-tissue Sarcoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Olaparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents